195 related articles for article (PubMed ID: 15593463)
21. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
Sarmiento JM; Heywood G; Rubin J; Ilstrup DM; Nagorney DM; Que FG
J Am Coll Surg; 2003 Jul; 197(1):29-37. PubMed ID: 12831921
[TBL] [Abstract][Full Text] [Related]
22. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract.
Schürmann G; Raeth U; Wiedenmann B; Buhr H; Herfarth C
World J Surg; 1992; 16(4):697-701; discussion 701-2. PubMed ID: 1413839
[TBL] [Abstract][Full Text] [Related]
23. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
24. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
[TBL] [Abstract][Full Text] [Related]
25. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors.
Moattari AR; Deftos LJ; Vinik AI
J Clin Endocrinol Metab; 1989 Oct; 69(4):902-5. PubMed ID: 2778040
[TBL] [Abstract][Full Text] [Related]
26. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
Gut P; Ruchała M
Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367
[TBL] [Abstract][Full Text] [Related]
28. Radiofrequency ablation of neuroendocrine liver metastases.
Elvin A; Skogseid B; Hellman P
Abdom Imaging; 2005; 30(4):427-34. PubMed ID: 15791486
[No Abstract] [Full Text] [Related]
29. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
Al-Efraij K; Aljama MA; Kennecke HF
Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
[TBL] [Abstract][Full Text] [Related]
30. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.
Desai DC; O'Dorisio TM; Schirmer WJ; Jung SS; Khabiri H; Villanueva V; Martin EW
Regul Pept; 2001 Jan; 96(3):113-7. PubMed ID: 11111016
[TBL] [Abstract][Full Text] [Related]
31. Chromogranin A assessment in patients with neuroendocrine neoplasm of the small bowel and carcinoid syndrome treated with somatostatin analogues.
Gut P; Czarnywojtek A; Ruchała M
Adv Clin Exp Med; 2020 Nov; 29(11):1319-1324. PubMed ID: 33269818
[TBL] [Abstract][Full Text] [Related]
32. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
[TBL] [Abstract][Full Text] [Related]
33. One stage surgery for synchronous liver metastasis from a neuroendocrine tumor of the colon. A case report.
Tartaglia N; Di Lascia A; Cianci P; Fersini A; Sanguedolce F; Iadarola R; Capuzzolo S; Neri V; Ambrosi A
Ann Ital Chir; 2017 Nov; 6():. PubMed ID: 29176078
[TBL] [Abstract][Full Text] [Related]
34. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of plasma chromogranin A in neuroendocrine tumours.
Tomassetti P; Migliori M; Simoni P; Casadei R; De Iasio R; Corinaldesi R; Gullo L
Eur J Gastroenterol Hepatol; 2001 Jan; 13(1):55-8. PubMed ID: 11204811
[TBL] [Abstract][Full Text] [Related]
36. A jejunal stromal tumour in a patient with metastatic neuroendocrine cancer of unknown origin; a rare coexistence, diagnostic and therapeutic challenge.
El Ali Z; Iwanik K; Sowiński J; Swora E; Grzymislawski M
Endokrynol Pol; 2009; 60(3):216-20. PubMed ID: 19569023
[TBL] [Abstract][Full Text] [Related]
37. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits.
Spadaro A; Ajello A; Morace C; Zirilli A; D'arrigo G; Luigiano C; Martino F; Bene A; Migliorato D; Turiano S; Ferraù O; Freni MA
World J Gastroenterol; 2005 Apr; 11(13):1987-90. PubMed ID: 15800991
[TBL] [Abstract][Full Text] [Related]
38. Partial hepatic resections for metastatic neuroendocrine tumors: perioperative outcomes.
Kinney MAO; Nagorney DM; Clark DF; O'Brien TD; Turner JD; Marienau ME; Schroeder DR; Martin DP
J Clin Anesth; 2018 Dec; 51():93-96. PubMed ID: 30098573
[TBL] [Abstract][Full Text] [Related]
39. Chromogranin A as serum marker of pituitary adenomas.
Gussi IL; Young J; Baudin E; Bidart JM; Chanson P
Clin Endocrinol (Oxf); 2003 Nov; 59(5):644-8. PubMed ID: 14616890
[TBL] [Abstract][Full Text] [Related]
40. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
